Ribonucleic Acid (RNA) Methylation Sequencing Market Global Report 2026

The ribonucleic acid (RNA) methylation sequencing market size has grown rapidly in recent years. It will grow from $0.66 billion in 2025 to $0.77 billion in 2026 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to growth in epigenetics and transcriptomics research funding, development of next generation sequencing platforms enabling high resolution rna analysis, increasing focus on cancer genomics and biomarker discovery, rising adoption of methylation sensitive immunoprecipitation techniques, expansion of academic and pharmaceutical research in rna biology.

The ribonucleic acid (RNA) methylation sequencing market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2030 at a compound annual growth rate (CAGR) of 15.0%. The growth in the forecast period can be attributed to integration of AI based methylation calling and sequence analysis tools, rising demand for precision medicine driven epitranscriptomic profiling, expansion of single molecule and long read sequencing technologies, increasing application of rna methylation in drug discovery and therapeutic targeting, growth in cloud enabled multi omics data integration platforms. Major trends in the forecast period include advancement of nanopore based direct rna methylation sequencing for real time epitranscriptomic profiling, increasing adoption of m6a immunoprecipitation sequencing for cancer biomarker discovery, integration of AI driven bioinformatics pipelines for rna modification detection, growing use of high throughput sequencing platforms for transcriptome wide methylation mapping, expansion of cloud based methylation data analytics for large scale genomic studies.

The growing demand for precision medicine is expected to drive the expansion of the ribonucleic acid (RNA) methylation sequencing market going forward. Precision medicine is a healthcare approach that tailors treatment and prevention strategies to an individual’s unique genetic profile, environment, and lifestyle. The demand for precision medicine is increasing due to advancements in genomics that enable healthcare providers to better understand a patient’s genetic characteristics, allowing for more targeted and effective treatments. Ribonucleic acid (RNA) methylation sequencing supports precision medicine by providing high-resolution mapping of RNA modifications that identify disease-specific signatures, enabling improved diagnosis, patient stratification, and the development of targeted therapies. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, personalized therapies experienced notable growth, with the FDA approving 16 new treatments for rare diseases in 2023, compared to six approvals in 2022. Therefore, the increasing demand for precision medicine is driving the growth of the ribonucleic acid (RNA) methylation sequencing market.

The increasing prevalence of cancer is expected to propel the growth of the ribonucleic acid (RNA) methylation sequencing market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can form tumors and disrupt normal body functions. The prevalence of cancer is rising due to the aging population, as older individuals are more likely to accumulate genetic mutations that contribute to uncontrolled cell growth. Ribonucleic acid (RNA) methylation sequencing supports cancer research and treatment by accurately mapping RNA modification patterns that regulate tumor development, progression, and therapeutic response, thereby enhancing biomarker discovery, early diagnosis, prognosis evaluation, and the development of targeted therapies. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase from the estimated 20 million cases reported in 2022. Therefore, the rising prevalence of cancer is driving the growth of the ribonucleic acid (RNA) methylation sequencing market.

The increasing pharmaceutical research and development (R&D) expenditure is expected to propel the growth of the ribonucleic acid (RNA) methylation sequencing market going forward. Pharmaceutical R&D expenditure refers to the total investment made by pharmaceutical and biotechnology organizations in the discovery, development, and testing of new drugs, therapies, and biotechnological innovations. Pharmaceutical research and development (R&D) expenditure is increasing due to the growing demand for innovative treatments for complex, chronic, and previously difficult-to-treat diseases, requiring sustained investment in advanced drug discovery and biotechnology research. Rising pharmaceutical research and development (R&D) expenditure supports ribonucleic acid (RNA) methylation sequencing by increasing funding for advanced molecular research, enabling the wider adoption of high-throughput sequencing technologies to analyze RNA modifications with greater precision, improve understanding of disease mechanisms, and accelerate the development of targeted and personalized therapies. For instance, in December 2024, according to the Office for National Statistics, a UK-based government agency, UK businesses invested $64.73 billion (拢50.0 billion) in research and development (R&D) in 2023, representing an increase of $1.83 billion (拢1.4 billion), or 2.9%, compared to 2022. Therefore, the rising pharmaceutical research and development (R&D) expenditure is driving the growth of the ribonucleic acid (RNA) methylation sequencing market.

Major companies operating in the ribonucleic acid (RNA) methylation sequencing market report are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., QIAGEN N.V., BGI Genomics Co. Ltd., Novogene Co. Ltd., Takara Bio Inc., Oxford Nanopore Technologies plc, Zymo Research Corp., CD Genomics LLC, Alida Biosciences Inc., Arraystar Inc., DirectSeq Bioscience, GenXPro GmbH, LC Sciences LLC, SeqMatic LLC, Illumina Inc., Pacific Biosciences of California Inc., New England Biolabs Inc., Diagenode SA, EpiGentek Group Inc.

North America was the dominating region in the ribonucleic acid (RNA) methylation sequencing market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) methylation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) methylation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.